In another study, it was shown that, compared to HCC patients susceptible to anti-PD-1 therapy, the number of NKG2D-positive cells in HCC patients resistant to anti-PD-1 therapy was significantly reduced. The gene discussed is KLRK1; the disease is hepatocellular carcinoma.